ASCENT-03 Results: Sacituzumab Govitecan in First-Line TNBC

Laura Huppert, MD, discusses the results of the phase 3 ASCENT-03 trial, which compared the antibody-drug conjugate sacituzumab govitecan with chemotherapy in patients with previously untreated advanced triple-negative breast cancer (TNBC) who were not candidates for PD-1/PD-L1 inhibitors. She also explains the clinical implications of these outcomes in the TNBC paradigm and the potential effect that the study allowing crossover might have on future study outcomes, such as the overall survival analysis.